Carotti Angelo, Stefanachi Angela, Raviña Enrique, Sotelo Eddy, Loza Maria Isabel, Cadavid Maria Isabel, Centeno Nuria B, Nicolotti Orazio
Dipartimento Farmacochimico, Università di Bari, via Orabona 4, 70125 Bari, Italy.
Eur J Med Chem. 2004 Oct;39(10):879-87. doi: 10.1016/j.ejmech.2004.07.008.
A number of 8-substituted-9-deazaxanthine derivatives (1,3-dialkyl-6-substituted-1H-pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-diones) were prepared and tested for their antagonistic activity at the recombinant human adenosine receptors, in particular at the A(2B) and A(2A) receptor subtypes. Compounds endowed with micromolar to nanomolar binding affinities, but with poor A(2B)/A(2A) selectivity, were obtained. Preliminary quantitative structure-affinity relationships suggested that the binding potency at the A(2B) receptor is mainly modulated by the electronic and lipophilic properties of the ligands.
制备了多种8-取代-9-脱氮黄嘌呤衍生物(1,3-二烷基-6-取代-1H-吡咯并[3,2-d]嘧啶-2,4(3H,5H)-二酮),并测试了它们对重组人腺苷受体,特别是A(2B)和A(2A)受体亚型的拮抗活性。得到了具有微摩尔至纳摩尔结合亲和力,但A(2B)/A(2A)选择性较差的化合物。初步的定量构效关系表明,A(2B)受体的结合效力主要受配体的电子和脂溶性性质调节。